| Name | Dup-721 |
| Description | DuP-721 is a broad-spectrum, orally active antibacterial agent that inhibits a variety of clinically susceptible and resistant bacteria, particularly [M. tuberculosis]. |
| In vitro | DuP-721 (1.5-4 μg/ml) effectively inhibits both conventional antituberculosis drug-susceptible and -resistant Mycobacterium tuberculosis strains without showing cross-resistance to any tested anti-tuberculosis drugs[1]. It is ineffective against M. avium and M. intracellulare up to 250 μg/ml, but inhibits M. gordonoe and M. fortuitum at 3.9 μg/ml, and M. kansasii and M. scrofulaceum at 1.95 μg/ml and 15.6 μg/ml, respectively[1]. |
| In vivo | DuP-721, the first oxazolidinone showed good activity against M. tuberculosis when given orally or parenterally to experimental animals. DuP-721 (oral gavage; 50-160 mg/kg) is protective against M. tuberculosis infection in mice. DuP-721 protects 100% of the infected animals at 50 mg/kg p.o. dose when administered daily for 17 days, and the same effect is observed at 160 mg/kg dose when the drug is administered only on day 11 and 12 post infection[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 100 mg/mL (354.70 mM), Sonication is recommended.
|
| Keywords | Dup-721 | M. tuberculosis | anti-tuberculosis | Mycobacterium tuberculosis | Inhibitor | M. intracellulare | inhibit | M. kansassi | Dup 721 | Dup721 | Antibiotic | Bacterial |
| Inhibitors Related | Neomycin sulfate | Dehydroacetic acid sodium | Ampicillin sodium | Methyl anthranilate | Doxycycline (hyclate) | Kanamycin sulfate | G-418 disulfate | Sulfamethoxazole sodium | Metronidazole | Doxycycline | Dimethyl sulfoxide | Crystal Violet |
| Related Compound Libraries | Bioactive Compound Library | Anti-Bacterial Compound Library | Orally Active Compound Library | Bioactive Compounds Library Max |
United States
